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Functional polymorphisms of UDP-glucuronosyltransferases
1A1, 1A6 and 1A8 are not involved in chronic pancreatitis
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Objectives Chronic pancreatitis (CP) is associated with
alcohol abuse, smoking and other dietary or environmental
factors. UDP-glucuronosyltransferases (UGTs) are phase II
detoxifying enzymes responsible for glucuronidation of
various exogenous and endogenous compounds. Genetic
variations, resulting in variable rates of glucuronidation, are
of toxicological and physiological importance and are
frequently associated with diseases. Recently, a genetic
polymorphism in UGT1A7 was possibly associated with an
increased risk for CP. We investigated whether
polymorphisms in the genes for UGT1A1, UGT1A6 and
UGT1A8 modified the risk for CP.
Methods DNA samples were obtained from 258 adult CP
patients with alcoholic (n 153), hereditary (n 25) or
idiopathic (n 80) origin. DNA from 140 healthy controls
was analyzed for comparison. Patients and controls were
all of Caucasian origin. Genetic polymorphisms in UGTs
were determined by PCR, eventually followed by
restriction-fragment-length-polymorphism analyses in all
subjects.
Results The distribution of the various alleles of UGT1A1,
UGT1A6 and UGT1A8 did not differ between CP patients
and healthy controls.
Conclusion These data suggest that genetic
polymorphisms in UGT1A1, UGT1A6 and in UGT1A8 do not
predispose to the development of CP in Caucasians.
Pharmacogenetics 14:351–357 & 2004 Lippincott Williams
& Wilkins
Pharmacogenetics 2004, 14:351–357
Keywords: UDP-glucuronosyltransferase; genetic polymorphism; chronic
pancreatitis
aDepartment of Medicine, Division of Gastroenterology and Hepatology,
University Medical Centre St Radboud, Nijmegen, The Netherlands and
bGastroenterology Department, MA´V Hospital Budapest, Podmaniczky Street
111, 1062 Budapest, Hungary.
Correspondence and requests for reprints to Mariette Verlaan, Department of
Medicine, Division of Gastroenterology and Hepatology, University Medical
Centre St Radboud, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Tel.: +31 24 3616520; fax: +31 24 3540103; e-mail: M.Verlaan@mdl.umcn.nl
Received 29 August 2003
Accepted 10 March 2004
Introduction
Chronic pancreatitis (CP) is a progressive inflammatory
disease, which eventually leads to functional impair-
ment of exocrine and/or endocrine function of the
organ [1–4]. The causes of CP are multifaceted. Most
cases have been attributed to alcohol abuse, but other
etiological factors such as heredity, smoking, anatomical
variations, and various metabolic disorders have also
been identified [5].
The elucidation of genes involved in hereditary forms of
CP has shed some insight in the pathogenesis of the
disorder [6]. In autosomal dominant forms of hereditary
CP, mutations in the cationic trypsinogen gene are linked
to the disease, whereas in cases with idiopathic CP,
mutations in pancreatic serine protease inhibitor Kazal
type 1 (SPINK1) have been detected. Although these
findings may explain development of CP in some pa-
tients, the pathogenesis in the majority of cases remains
unknown, and it is likely that there are additional genetic
factors modifying the susceptibility towards CP [1,3].
The mechanism of tissue damage in CP is unclear.
Various toxins have been implied as a possible cause,
including oxidative stress from endogenous origin or
chemical stress by environmental or lifestyle related
xenobiotics [7].
UDP-glucuronosyltransferases (UGTs), a family of bio-
transformation enzymes located in the endoplasmic
reticulum of many cell types, contribute to the detox-
ification of a number of common, potentially harmful
chemicals, by catalyzing the addition of the glucuronyl
group from UDP-glucuronic acid, to a wide variety of
endogenous or exogenous compounds [8]. The result-
ing metabolites in general are less biologically active
and possess increased water solubility, enhancing their
biliary or renal excretion. Beside detoxification how-
ever, biotransformation reactions catalyzed by UGT
enzymes in a minority of cases, can result in bioactiva-
tion of molecules. Reactive intermediates and toxic
metabolites can be liberated with detrimental conse-
quences [9–11].
UGT enzymes have been classified on the basis of
sequence homology into the UGT1A, UGT2A and 2B
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subfamilies [12]. Family 1A isoforms are derived from a
single gene locus on chromosome 2q37 [13]. In humans
the UGT1A is composed of at least nine functional
proteins (UGT1A1, UGT1A3–UGT1A10), encoded by
five exons. Exons 2 to 5 are shared by all UGT1A
genes, whereas exon 1 is different and determines the
specific properties of the UGT1A members [12].
Family 2 enzymes include UGT2A1, 2B4, 2B7, 2B10,
2B11, 2B15 and 2B17, encoded by separate genes,
mapped on chromosome 4 [14]. Most human UGT
isoforms are expressed in the liver, but high UGT
expression levels have also been reported extrahepati-
cally, indicating that other organs also play a major role
in glucuronidation [15–17].
Recently, functional polymorphisms in the genes en-
coding the various UGT1 family members have been
discovered [18–21]. UGT1A1 has been most exten-
sively studied due to its importance in clearing bilir-
ubin. So far over 100 different substrates have been
identified, including endogenous estrogens and numer-
ous xenobiotic compounds, such as phenols and flavo-
noids [22–24]. A genetic polymorphism in the promotor
region of UGT1A1, which contains an extra TA repeat
(TA)7TAA instead of (TA)6TAA, results in reduced
gene expression with concomitant reduction in enzyme
activity [25–27]. This so-called TATA box mutation
(UGT1A1*28) in Caucasians may lead to hyperbilirubi-
nemia and is associated with Gilbert’s syndrome
[28,29].
UGT1A6 has the capacity to glucuronidate many
xenobiotic phenols and genetic defects may lead to
lower rates of metabolism of a number of phenols [30].
Two missense mutations on the same allele of UGT1A6
(UGT1A6*2) result in T181A and R184S amino acid
substitutions with reduced enzyme activity [30,31]. In
most cases both mutations are linked, although the
single R184S mutation has been identified incidentally.
The presence of an UGT1A6*2 allele may reduce the
protective effect of aspirin against colon adenomas [32].
UGT1A8 in the gastrointestinal tract is expressed
exclusively extrahepatic, and might play an important
role in first pass metabolism [18]. The UGT1A8
enzyme participates in the metabolism of drugs, dietary
and environmental carcinogens in addition to endogen-
ous substrates [33]. Recently, three allelic variants of
the UGT1A8 have been identified: UGT1A8*1,
UGT1A8*2 and UGT1A8*3, resulting from two amino
acid substitutions at positions 173 and 277. Both
UGT1A8*1 and UGT1A8*2 gene products have similar
catalytic properties, whereas presence of the UGT1A8*3
allele leads to dramatically reduced activity towards
substrates [20].
Recently, genetic polymorphisms in another extrahepa-
tic member of the UGT family (UGT1A7) was possibly
linked to an increased risk for CP and pancreatic cancer
[34]. We therefore hypothesized that toxins, either of
endogenous or exogenous origin and potential sub-
strates for UGT1A1, 1A6 or 1A8, could be also involved
as causative agents for CP. Since genetic variations in
enzymes metabolizing such molecules could also mod-
ify the risk for CP, we investigated the possible
association between CP and genetic polymorphisms in
UGT1A1, UGT1A6 and UGT1A8, in a cohort of non-
selected Caucasian CP patients.
Methods
Subjects
The study was approved by the local medical ethical
review committee and all subjects gave their written
informed consent. All subjects studied were Caucasians
of Dutch (50%) and Hungarian (50%) extraction. The
CP patients group consisted of 258 adult patients (164
males, 94 females). Twenty-five patients (10%) had a
family history of CP (HCP), 153 patients (59%) had
alcohol-induced CP (ACP) and 80 patients (31%) were
classified as having idiopathic chronic pancreatitis (ICP).
The clinical diagnosis of CP was based on one or more
of the following criteria: presence of typical complaints
(recurrent upper abdominal pain, radiating to the back,
relieved by leaning forward or sitting upright and
increased after eating); suggestive radiological findings,
such as pancreatic calcifications or pseudocysts, and
pathological findings (pancreatic ductal irregularities
and dilatations) revealed by endoscopic retrograde
pancreaticography or magnetic resonance imaging of
the pancreas before and after stimulation with secretin.
HCP was diagnosed on the basis of two first-degree
relatives or three or more second-degree relatives in
two or more generations, which suffered from recurrent
acute pancreatitis or chronic pancreatitis for which
there was no precipitating factor. ACP was diagnosed in
patients who consumed more than 60 g (females) or
80 g (males) of ethanol per day for more than 2 years.
Four of the 153 ACP patients also suffer from liver
cirrhosis. Patients were classified as having ICP when
precipitating factors such as alcohol abuse, trauma,
medication, infection, metabolic disorders and/or a posi-
tive family history were all absent.
For comparison, we collected a control group consisting
of 140 adult healthy subjects (53 males, 87 females)
recruited by advertisement in a local paper.
Blood
For DNA extraction, blood samples were collected into
EDTA tubes and stored at 208C until use. DNA was
isolated from whole blood using the Pure Gene DNA
isolation kit according to the instructions from the
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manufacturer (Gentra Systems, Minneapolis, MN,
USA), diluted to 50 mg/ml and stored at 48C.
Genotyping
In the UGT1A1 gene, the number of TA-repeats in the
promotor region was analyzed using the PCR conditions
and primers (C and D) as described before [26].
Amplification was confirmed by agarose electrophoresis
before fragments were resolved on 13% polyacrylamide
gels (19 : 1 acrylamide/bisacrylamide; Biorad) in Tris-
borate EDTA buffer as described before [35]. Gels
(20 3 20 3 0.075 cm) were run at 400 V for 4 h and
stained with ethidium bromide for 15 min. Fragments
of 98 bp indicate for the UGT1A1*1 allele, containing
six TA repeats, and fragments of 100 bp indicate for
the UGT1A1*28 allele, containing seven TA repeats.
The T181A and R184S polymorphisms in exon 1 of the
UGT1A6 gene were studied using polymerase chain
reaction amplification according to the method recently
described [36]. Subsequently the PCR product was
digested using restriction enzymes NsiI for the T181A
substitution and Fnu4HI for the R184S substitution.
Digested samples were run on a 3% agarose gel and
stained with ethidium bromide. The UGT1A6*2 allele
contains an additional restriction site for both restriction
enzymes used here, which is not present in the
UGT1A6*1 allele.
Both polymorphisms in the UGT1A8 gene correspond-
ing with amino acid substitutions at position 173 and
277 were analyzed with two separate PCRs followed by
restriction fragment length polymorphism analysis. The
forward and reverse primers used for the PCR to detect
the A173G substitution were 59-CAGTTCTCTCATG
GCTCGCA-39 and 59-GTGTGGCTGTAGAGATCAT
ATGCT-39, respectively. The PCR conditions were
4 min at 958C, then 35 cycles of 30 s at 958C, 1 min at
588C, and 1 min at 728C, and finally an elongation step
at 728C for 7 min. A 750 bp product was amplified and
aliquots of 5 l of the PCR mixture were directly
digested for one hour at 378C with 10 units of the
restriction enzyme AluI, followed by electrophoresis on
3% agarose gel, containing ethidium bromide. The
UGT1A8*2 allele (A173G) contains only one restriction
site for AluI, instead of two restriction sites for the
UGT1A8*1 and UGT1A8*3 alleles (Fig. 1a). To detect
the C277Y substitution by PCR, the forward and
reverse primers 59-TCTTCATTGGTGGTATCAGCT-
39 and 59-AAAATTTGATAACTGATGAGTACATA-
39 were used, respectively. The annealing temperature
for this PCR was 1 min 498C, with remaining similar
PCR conditions. The last G of the forward primer
creates a restriction site for PvuII; the digestion of the
215 bp PCR product with PvuII was carried out under
similar conditions as described above. The UGT1A8*3
allele (C277Y) contains no restriction site for PvuII,
distinct from the UGT1A8*1 and UGT1A8*2 alleles,
which have one PvuII restriction site (Fig. 1b).
Statistical analyses
Data were analyzed by SAS version 8.0. Differences in
the baseline characteristics of patients and controls
were estimated with Fisher’s exact test and the t-test.
Chi-square statistics were used to estimate differences
in the presence of allele frequencies in UGT1A1,
UGT1A6 and UGT1A8 among the different study
groups. When one of the genotypes has expected
counts of less than 5, the Chi-square test may not be a
valid test, and then we used Fisher’s exact test. Odds
ratios (OR) with 95% confidence interval (95% CI)
were calculated by logistic regression analysis for the
allele frequencies in UGT1A1 and for the UGT1A8*3
compared to the UGT1A8*1 and UGT1A8*2 alleles
taken together.
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Identification of UGT1A8 polymorphisms using restriction fragment length polymorphism analysis. Electrophoresis patterns of PCR fragments after
digestion with AluI for the A173G polymorphism (a) and after digestion with PvuII for the C277Y polymorphism (b). M: 100 bp marker, lanes 1:
homozygosity for the common allele, lanes 2: heterozygosity, lane 3: homozygosity for the variant allele. Homozygosity for the C277Y polymorphism
was not found. The sizes of the PCR fragments are indicated by arrows.
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The distribution of each allele frequency among the
control population was tested whether it fitted the
Hardy–Weinberg equilibrium.
In total, three genetic polymorphisms of the UGT1A
family were analyzed. Because the different UGT1A
isoforms are derived from one single gene locus, we
corrected for multiple testing with Bonferroni, meaning
that P values of less than 0.017 instead of 0.05 were
considered to represent statistical significance.
Finally, we examined the co-occurrence of the alleles
encoding less active UGT enzymes, UGT1A*28,
UGT1A6*2 and UGT1A8*3 among CP patients and
control subjects using the Spearman rank correlation
test.
Results
Characteristics of patients and controls
Characteristics of patients with CP and healthy controls
are denoted in Table 1. There is a difference in gender
between patients and healthy controls, with more
female subjects in the latter group (P , 0.05; Table 1).
The mean age of CP patients is higher compared to
that of the control group (P , 0.05; Table 1), except for
the HCP patients, since these patients develop CP at a
younger age than the other CP patients.
Although data on smoking habits was only available
from a limited number of subjects, significantly more
ACP patients smoked compared to healthy controls
(P , 0.05; Table 1).
UGT1A1, UGT1A6 and UGT1A8 polymorphisms
All UGT polymorphisms investigated are summarized
in Table 2. Allele frequencies of the polymorphisms in
the three UGT1A genes investigated here are reported
in Table 3.
There were no statistical differences in the distribution
of UGT1A1*1 and UGT1A1*28 alleles among patients
with HCP, ACP, ICP separately or in all CP patients
combined vs. healthy control subjects (Table 3). We
were unable to detect individuals carrying five or eight
TA repeats in the TATA box of the promotor.
The distribution of the UGT1A6*1, UGT1A6*2 and
UGT1A6 R184S alleles in the different CP patient
groups and control subjects does not demonstrate any
statistical difference either (Table 3). There were no
individuals with a single T181A variant, whereas
approximately 2% of all subjects carried the single
R184S variant.
UGT1A8 genotyping did not show a different distribu-
tion of the UGT1A8*1, UGT1A8*2 and UGT1A8*3 allele
among patients compared to healthy control subjects
(Table 3). Since UGT1A8*1 and UGT1A8*2 alleles may
have similar catalytic properties, we combined these
alleles, but this did not yield in significant differences
between CP patients and controls. No statistical differ-
ence was observed in the frequencies of the UGT1A8*3
allele (Table 3).
In addition, the co-occurrence of UGT1A*28 and
UGT1A6*2 polymorphism were examined and strong
association was found in both the CP patients and
control group (r ¼ 0.66, P , 0.0001 and r ¼ 0.78, P ,
0.0001, respectively). There was no statistically signifi-
cant difference in the distribution of this combination
of alleles between CP patients and healthy controls
(P ¼ 0.58). Because of the relatively low frequency of
UGT1A8*3 allele, the combination of all three alleles
encoding for less active UGT enzymes was not exam-
ined.
For each of the three UGT1A genes the distribution of
the allele frequencies among the control population
was separately tested and found to fit with the assump-
tion of the Hardy–Weinberg equilibrium.
Discussion
Genetic variations that may reduce expression or activ-
ity of phase II biotransformation enzymes are of
toxicological and physiological importance and are fre-
quently associated with a wide variety of diseases.
Glucuronidation catalyzed by UGTs is one of the most
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1 Main characteristics of patients with chronic pancreatitis
and healthy controls
Characteristic HCP ACP ICP All patients Controls
n 25 153 80 258 140
Gender
Male/female 9/16 117/36* 38/42 164/94* 53/87
Age (years)
Mean  SD
38  21 51  9* 48  17* 49  14* 44  16
Smoking
(yes/no)
8/6 91/7 31/11 130/24 68/45
Unknown 11 55 38 104 27
HCP: hereditary chronic pancreatitis; ACP: alcoholic chronic pancreatitis; ICP:
idiopathic chronic pancreatitis.
*P-value , 0.05 as compared to control group.
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important mechanisms involved in host defence against
xenobiotic chemicals and endogenous toxins. Xenobio-
tically or endogenously mediated cellular injury might
play a role in the etiology of CP [37–39]. In the present
study we investigated the possible association between
CP and genetic polymorphisms in three UGT1A iso-
enzymes that are associated with changes in enzyme
activity and function and are potentially expressed in
pancreatic tissue [20,25–27,30,31].
We found that frequencies of genetic polymorphisms in
UGT1A1, UGT1A6 and UGT1A8 in Caucasian healthy
control subjects were not different to those in CP
patients. This suggests that individuals bearing the
UGT alleles, encoding for less active enzymes do not
have a higher risk for developing CP.
The frequency of the UGT1A1*28 allele was 34% in
CP patients compared to 28% in the controls. This is
comparable to the frequencies (29–39%) reported in
Caucasian control subjects by several other groups
[27,30,40–42]. The frequency of the UGT1A6*2 allele
in both CP patients and healthy controls was estimated
at 34%, which is appreciably higher than the 16.8%
reported by Ciotti et al. [31], but not different from
30.7% and 32.5% found by Lampe et al. [30] and Ko¨hle
et al. [42], respectively. The allele frequency of
UGT1A8*3, 1.6% for CP patients and 1.4% for healthy
controls, was similar to 2.2%, reported by Huang et al.
[20].
UGT1A7 is the only other member of the UGT1A
family which has been recently investigated in relation
to pancreatic diseases. Genetic polymorphisms possibly
associated with a low detoxification activity of UGT1A7
have recently been identified by Ockenga et al. as a risk
factor for alcohol-induced CP and pancreatic carcinoma
[34]. They detected a much higher frequency of the
UGT1A7*3 allele in patients (25–37%) as compared to
healthy controls (21%). As UGT1A7 catalyzes the
glucuronidation of several tobacco smoke carcinogens,
and smoking in addition to alcohol abuse, appears to be
a risk factor for CP, reduced enzyme activity might
confer a higher risk for CP. In addition, UGT1A7 is
reported to be the predominant UGT1A transcript in
human pancreas [34]. In contrast to Ockenga et al., who
did find a positive association between the low detox-
ification allele UGT1A7*3 and the risk for alcoholic
chronic pancreatitis and pancreatic cancer, results from
our laboratory indicate that individuals bearing less
active UGT1A7 alleles do not run a higher risk for
pancreatic diseases (unpublished observations). We
collected a large multi-national cohort of patients with
either acute (n ¼ 153) or CP (idiopathic/hereditary n ¼
266, alcoholic n ¼ 318) or pancreatic cancer (n ¼ 297)
and compared the genetic polymorphisms in the
UGT1A7 gene with 1532 controls. Using melting curve
analysis with fluorescence resonance energy transfer
probes and restriction fragment length polymorphism
analysis, we were unable to detect differences in
UGT1A7 frequency distribution between patients and
controls. Most notably, the frequency of the UGT1A7*3
risk allele was comparable between patients (31–44%)
and controls (40%). The discrepancies between our
study and that of Ockenga et al. [34] most likely stem
from differences in (a) selection of the control group,
(b) sample size and (c) the different methodology used
in both studies. The UGT isoenzymes UGT1A1 and
UGT1A6, investigated in our study do not specifically
glucuronidate benzo[a]pyrenes or other toxic com-
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 3 Allele frequencies of UGT1A1, UGT1A6 and UGT1A8 in patients with chronic













*1 0.68 0.67 0.66 0.66 0.72
*28 0.32 0.33 0.34 0.34 0.28
P-value* 0.61 0.23 0.15 0.14
OR (95% CI) 1.2 (0.6–2.3) 0.8 (0.6–1.5) 1.4 (0.9–1.8) 1.3 (0.9–1.8)
UGT1A6
*1 0.65 0.63 0.65 0.64 0.64
*2 0.30 0.34 0.34 0.34 0.34
R184S 0.04 0.03 0.01 0.02 0.02
P-value* 0.64 0.89 0.48 0.99
UGT1A8
*1 0.82 0.79 0.83 0.80 0.73
*2 0.16 0.20 0.15 0.18 0.25
*3 0.02 0.01 0.02 0.02 0.01
P-value* 0.35 0.33 0.04 0.06
OR (95% CI)** 0.8 (0.2–12.9) 1.1 (0.3–4.4) 1.3 (0.3–6.0) 1.1 (0.3–3.7)
HCP: hereditary chronic pancreatitis; ACP: alcoholic chronic pancreatitis; ICP: idiopathic chronic
pancreatitis; OR: odds ratio; 95% CI: 95% confidence interval.
*P-values, estimated with Chi-square test or with Fisher exact test, when cells have expected counts less than
5.
**OR 95% CI for the UGT1A8*3 allele compared to the UGT1A8*1 and UGT1A8*2 alleles taken together.
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pounds from cigarettes [8], whereas UGT1A8 does
[20]. However, it is not known yet whether the
UGT1A8 enzyme is substantially expressed in pancrea-
tic tissue.
UGTs are known to exist as a superfamily of enzymes
with a broad substrate profile, however substrate speci-
ficity of the various isoenzymes remains poorly defined.
Isoenzymes may exhibit overlapping substrate specifi-
cities, and one isoenzyme may compensate low activity
of another, explaining why individuals bearing one low
detoxification activity allele do not confer a higher risk
for CP. Apparently the UGTs investigated here are not
exclusively responsible for the metabolism of a particu-
lar drug or chemical associated with CP, or are not the
predominant UGTs present in pancreatic tissue as
might be for UGT1A7 in the pancreas, and therefore
these polymorphisms did not show to be of major
clinical significance.
Genetic polymorphisms in UGT1A1 and UGT1A6 are
known to play important roles in disease susceptibility.
Homozygosity or heterozygosity for genetic polymorph-
isms in UGT1A1 may lead to hyperbilirubinemia (Crig-
ler–Najjar or Gilbert’s syndromes), because activity
towards conjugation of bilirubin is restricted to
UGT1A1 [17]. Nevertheless, the UGT1A1 promotor
polymorphism, which is strongly linked to the UGT1A6
polymorphisms studied here [36], is reported to be
positively associated with breast cancer in premenopau-
sal African-American women, but not in Caucasians
[40,43]. In addition, the UGT1A6*2 allele is found to be
associated with reduced protection against colon adeno-
mas by aspirin [32].
In summary, we failed to detect associations between
CP and genetic polymorphisms in UGT1A1, UGT1A6
and UGT1A8 in Caucasians. Our results might suggest
that presence of low detoxification activity of these
UGT enzymes does not predispose to CP.
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